Distributor inventory | Vial
Insulin glulisine 100 IU/mL (rDNA origin) injection
Treatment of diabetes mellitus (Type 1 and Type 2) to control high blood sugar; used as rapid-acting mealtime insulin with a longer-acting basal insulin regimen as advised
Insulin glulisine is a rapid-acting insulin analog that replaces/augments insulin to help glucose enter muscle and fat cells and reduces glucose production by the liver. It lowers blood sugar quickly after injection, especially around meals.
Injection (vial): Use only as prescribed. Typically injected subcutaneously shortly (0–15 minutes) before a meal or immediately after starting a meal. Dose and timing depend on blood glucose, meal pattern and other insulin/antidiabetic therapy. Use appropriate insulin syringe; do not share needles/syringes. May be used in insulin pumps if specifically advised; follow device instructions and healthcare guidance.
Common side effects of APIDRA 100 IU/MI VIAL may include:
Risk of hypoglycaemia—carry glucose/sugar and monitor blood glucose regularly. Rotate injection sites to reduce lipodystrophy. Do not use during episodes of hypoglycaemia. Use with caution in kidney or liver impairment (may need dose adjustment). Severe allergy to insulin or excipients is a contraindication—seek urgent care for breathing difficulty, swelling or generalized rash. Illness, stress, meal changes and exercise can alter insulin needs. Use only clear, colorless solution; do not use if cloudy/particles. Do not mix with other insulins unless specifically advised by doctor (and follow product guidance).
